← Leaderboards
Richard Sang-Yong Lee
Boston Children'S Hospital
$4,165,332
Attributed
$6,154,323
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $582.8K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,154,323 · 5
By mechanism
R01$4,133,073 · 2
U01$1,166,660 · 1
K08$754,590 · 1
R56$100,000 · 1
Top collaborators
- Rosalyn M Adam5 shared
- Marsha A Moses5 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Carlos R Estrada$2,551,712
- Nina Mann$1,019,813
- Sila Kurugol$3,163,140
- Lalit Kumar$233,208
- Hanno Steen$18,284,696
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortProteinsUrinaryUrineProteomeInsightChildPrenatalObstructionSamplingBiological MarkersKidneyBaseValidationProteomicsPostnatalDiagnosticClinically RelevantMass Spectrum AnalysisClinical ManagementBostonPediatric HospitalsProspectiveComplement
Grant awards (22)
NIMBLE: Non-Invasive Markers of Bladder Deterioration$555,962
R01 · FY2025 · DK · contact PI
NIMBLE: Non-Invasive Markers of Bladder Deterioration$533,723
R01 · FY2024 · DK · contact PI
NIMBLE: Non-Invasive Markers of Bladder Deterioration$555,962
R01 · FY2023 · DK · contact PI
NIMBLE: Non-Invasive Markers of Bladder Deterioration$582,838
R01 · FY2022 · DK · contact PI
NIMBLE: Non-Invasive Markers of Bladder Deterioration$582,838
R01 · FY2021 · DK · contact PI
Early Validation of Urinary Biomarkers of Renal Obstruction$100,000
R56 · FY2019 · DK · contact PI
Discovery, Validation and Clinical Application of Novel, Non-Invasive Biomarkers$233,332
U01 · FY2018 · DK
Early Validation of Urinary Biomarkers of Renal Obstruction$265,500
R01 · FY2017 · DK · contact PI
Discovery, Validation and Clinical Application of Novel, Non-Invasive Biomarkers$233,332
U01 · FY2017 · DK
Early Validation of Urinary Biomarkers of Renal Obstruction$265,500
R01 · FY2016 · DK · contact PI
Discovery, Validation and Clinical Application of Novel, Non-Invasive Biomarkers$233,332
U01 · FY2016 · DK
Early Validation of Urinary Biomarkers of Renal Obstruction$264,875
R01 · FY2015 · DK · contact PI
Discovery, Validation and Clinical Application of Novel, Non-Invasive Biomarkers$233,332
U01 · FY2015 · DK
Early Validation of Urinary Biomarkers of Renal Obstruction$263,375
R01 · FY2014 · DK · contact PI
Discovery, Validation and Clinical Application of Novel, Non-Invasive Biomarkers$233,332
U01 · FY2014 · DK
Early Validation of Urinary Biomarkers of Renal Obstruction$262,500
R01 · FY2013 · DK · contact PI
The effect of congenital renal obstruction on the urinary proteome in infants$145,330
K08 · FY2011 · DK · contact PI
The effect of congenital renal obstruction on the urinary proteome in infants$145,330
K08 · FY2010 · DK · contact PI
The effect of congenital renal obstruction on the urinary proteome in infants$145,330
K08 · FY2009 · DK · contact PI
The effect of congenital renal obstruction on the urinary proteome in infants$54,000
K08 · FY2009 · DK · contact PI
The effect of congenital renal obstruction on the urinary proteome in infants$132,300
K08 · FY2008 · DK · contact PI
The effect of congenital renal obstruction on the urinary proteome in infants$132,300
K08 · FY2007 · DK · contact PI